Evidence (14922 claims)
Search and filter individual claims pulled from the papers. Looking for a specific finding ("what's the effect on wages?"), you're in the right place. Want to compare whole outcome categories against each other instead? Use the Evidence Explorer.
The board below groups claims two ways: by broad theme (nine paper-level topics) and by outcome category (the 34 claim-level outcomes that the Explorer and Syntheses also use).
Browse by theme
Nine broad, paper-level topics. Click one to filter the claims below.
Adoption
9047 claims
Filter claims →
Productivity
8066 claims
Filter claims →
Governance
7278 claims
Filter claims →
Human-AI Collaboration
6912 claims
Filter claims →
Org Design
4439 claims
Filter claims →
Innovation
4359 claims
Filter claims →
Labor Markets
3652 claims
Filter claims →
Skills & Training
3018 claims
Filter claims →
Inequality
2160 claims
Filter claims →
Claims by outcome category
Counts by direction of finding. These are the same 34 outcome categories the Explorer compares and the Syntheses are written for. A linked row has a published synthesis.
| Outcome | Positive | Negative | Mixed | Null | Total |
|---|---|---|---|---|---|
| Other | 795 | 210 | 105 | 955 | 2131 |
| Governance & Regulation | 886 | 414 | 197 | 126 | 1654 |
| Organizational Efficiency | 826 | 204 | 129 | 87 | 1257 |
| Technology Adoption Rate | 681 | 259 | 128 | 110 | 1189 |
| Research Productivity | 464 | 138 | 65 | 349 | 1028 |
| Output Quality | 503 | 196 | 61 | 53 | 813 |
| Decision Quality | 351 | 180 | 84 | 51 | 673 |
| AI Safety & Ethics | 238 | 288 | 71 | 34 | 637 |
| Firm Productivity | 455 | 58 | 92 | 20 | 631 |
| Market Structure | 186 | 172 | 123 | 25 | 511 |
| Task Allocation | 222 | 70 | 76 | 34 | 407 |
| Innovation Output | 238 | 28 | 48 | 18 | 334 |
| Skill Acquisition | 177 | 62 | 62 | 17 | 318 |
| Employment Level | 107 | 57 | 108 | 13 | 287 |
| Fiscal & Macroeconomic | 135 | 72 | 44 | 26 | 284 |
| Firm Revenue | 172 | 50 | 28 | 5 | 256 |
| Consumer Welfare | 121 | 68 | 45 | 12 | 246 |
| Task Completion Time | 183 | 33 | 10 | 13 | 240 |
| Inequality Measures | 45 | 126 | 50 | 6 | 227 |
| Worker Satisfaction | 95 | 74 | 23 | 12 | 204 |
| Error Rate | 77 | 98 | 11 | 4 | 190 |
| Regulatory Compliance | 84 | 73 | 17 | 7 | 181 |
| Automation Exposure | 61 | 61 | 27 | 14 | 166 |
| Training Effectiveness | 98 | 21 | 14 | 19 | 154 |
| Wages & Compensation | 78 | 37 | 25 | 6 | 146 |
| Developer Productivity | 105 | 18 | 14 | 6 | 144 |
| Team Performance | 87 | 17 | 28 | 10 | 143 |
| Job Displacement | 12 | 83 | 23 | 1 | 119 |
| Hiring & Recruitment | 53 | 8 | 8 | 3 | 72 |
| Social Protection | 39 | 17 | 8 | 2 | 66 |
| Creative Output | 32 | 20 | 8 | 3 | 64 |
| Skill Obsolescence | 5 | 50 | 6 | 1 | 62 |
| Labor Share of Income | 17 | 20 | 17 | — | 54 |
| Worker Turnover | 15 | 15 | — | 3 | 33 |
| Industry | — | — | — | 1 | 1 |
Findings are consistent with the 'computers are social actors' (CASA) framework: people respond to computers as social actors, so social/affective cues (not just whether a partner is human) shape collaboration outcomes.
Theoretical interpretation offered by the authors, supported by empirical patterns in the experiment (significant moderation by emotion and mediation by service empathy despite no main effect of partner type).
Policy/managerial implication: organizational structures and incentives (e.g., TMT diversity, ESOPs) are effective levers to sustain managerial attention to employee welfare and mitigate the negative effects of deep AI penetration on ECSR.
Inference from empirical moderator results (TMT diversity and ESOP interactions) combined with theoretical ABV/dual-agent argument; paper includes managerial and policy recommendations based on these findings.
Employee stock ownership (ESOP) moderates the relationship by flattening and right-shifting the inverted U, aligning employee incentives and preserving employee-focused attention as AI adoption deepens.
Interaction terms between AI (and AI^2) and ESOP presence/level show mitigated negative effects of high AI adoption on ECSR and a later turning point; based on panel regressions with controls and robustness checks on the 2,575-firm sample.
Top management team (TMT) functional diversity moderates the AI–ECSR curve by flattening it and right-shifting the peak, delaying and mitigating negative attention shifts from employees to AI.
Interaction of AI (and AI^2) with a TMT functional diversity measure in panel regressions indicates a less pronounced inverted U and a later turning point for firms with more diverse TMTs; analysis uses the main panel (2,575 firms, 2013–2023) with robustness checks.
At low-to-moderate levels of AI adoption, AI increases managerial attention to employees and raises ECSR (human attention gain mechanism).
Positive slope of the estimated AI–ECSR relationship at lower AI values implied by the significant linear AI term in the quadratic panel model; theoretical framing via an attention-based view (ABV) and dual-agent model; empirical results interpreted as consistent with increased managerial attention and higher ECSR at low-to-moderate AI adoption. (Sample: 2,575 firms, 2013–2023.)
AI-mediated collaboration will create new organizational roles and governance structures, such as AI mediators and verification/oversight roles.
Conceptual discussion of organizational implications and illustrative role examples; no organizational case studies with sample sizes reported.
Autonomous AI agents can automate routine coordination tasks, follow-up, and some task execution, thereby reducing human coordination overhead.
Paper uses conceptual mapping of agent capabilities to coordination/execution functions and provides illustrative case scenarios; no experimental or field data presented.
Multimodal systems (integrating text, speech, images, video) broaden communication channels and thus can improve the range and fidelity of mediated communication.
Conceptual argument and illustrative examples in the paper describing how multimodal integration maps to communication functions; no empirical validation reported.
Multilingual language models reduce language barriers by translating and normalizing meaning across languages.
Conceptual synthesis of capabilities (multilingual LMs) and mapping to coordination function (translation/normalization); supported in paper by illustrative examples rather than empirical testing.
Trust in AI should be conceptualized as a socio-technical, team-level mechanism (trust calibration) that mediates between AI design/enablers and downstream collaboration and performance, rather than an individual-level stable attitude.
Theoretical synthesis combining findings from the thematic analysis of 40 interviews with socio-technical systems theory (STS) and adaptive structuration theory (AST) to propose an initial and revised conceptual model linking enablers → trust-calibration practices → collaboration dynamics → performance.
Five enablers support effective trust calibration: transparency/explainability, clear role definitions, good user experience (UX), supportive cultural norms, and timely system feedback.
Synthesized from recurring themes in the interview data (N=40) where respondents identified these factors as facilitating appropriate reliance on AI in project settings; coded and aggregated through thematic analysis.
Performance and reward structures must be redesigned to value oversight, hypothesis testing, escalation and governance behaviours that mitigate model risk but may not immediately increase output.
Managerial recommendation derived from the framework and organizational reward literature; no empirical evaluation provided.
Firms need new metrics to decompose value created by humans, AI, and their interaction (to distinguish complementarities versus substitution).
Analytic implication derived from the framework and literature on productivity measurement; presented as a recommendation for empirical work rather than tested evidence.
Symbiarchic leadership is a practical, HR‑oriented framework for leading integrated human–AI “cyber teams,” specifying four linked leadership practices that make AI a co‑actor in knowledge work while preserving human judgement, accountability and organizational legitimacy.
Paper's central proposition based on theoretical synthesis of academic literature on human–AI collaboration, hybrid teams and digital‑era leadership plus illustrative practitioner examples; no original empirical data or experiments.
Policies improving data sharing, standardization, and model transparency would increase overall welfare by reducing duplication and improving model performance.
Policy argumentation in the paper drawing on economic theory and examples where shared datasets/standards improved research productivity.
Organizations that tightly integrate AI teams with experimental groups achieve higher productivity.
Case studies and internal metrics cited in the paper showing improved throughput and candidate progression in integrated teams versus siloed approaches.
Value accrues to firms that control high-quality data, integrated platforms, and wet-lab validation—data and experimental capacity are strategic assets.
Market and organizational analysis in the paper citing examples of firms leveraging proprietary data/platforms and wet-lab capabilities to advance candidates more effectively.
AI reduces time and cost in early-stage discovery (discovery-to-candidate), lowering per-candidate screening and design costs.
Reported case studies and cost/time comparisons in the paper showing faster candidate identification and reduced experimental burden in early stages; aggregated industry claims summarized.
Several AI-guided molecules have entered clinical trials and show encouraging early-phase indicators.
Industry reports and trial registries summarized in the paper reporting multiple AI-guided programs reaching Phase I/II; company disclosures and early-phase biomarker or safety readouts referenced.
Recommendations for policy include investing in public data infrastructure and standards, promoting regulatory clarity for AI validation, and supporting equitable access to AI-driven innovations.
Policy recommendations derived from synthesis of challenges and potential remedies presented in the narrative review; based on conceptual policy analysis and examples rather than empirical testing of interventions.
Policies that incentivize interoperable, privacy-preserving data sharing (e.g., federated data, common standards) can reduce entry barriers and improve social returns from AI in drug R&D.
Policy analysis and recommendations from the review, supported by conceptual arguments and examples of federated/privacy-preserving platforms; limited empirical validation of large-scale impact.
AI has the potential to raise R&D productivity by shortening timelines and reducing certain failure modes, thereby increasing the net present value (NPV) of successful drug projects.
Economic reasoning and projections based on documented process improvements in the reviewed studies and reports; not validated by longitudinal, generalized financial analyses in the literature.
AI enhances post-market safety signal detection using real-world data analytics.
Industry and regulatory reports and published studies in the review documenting improved detection or earlier identification of safety signals in pharmacovigilance applications using ML on real-world datasets.
AI-enabled adaptive and enrichment trial designs increase trial efficiency and statistical power.
Methodological studies, clinical-trial case studies, and regulatory guidance summarized in the review showing applications of ML to adaptive/enrichment designs; evidence mainly illustrative and context-specific.
AI improves predictive toxicity and ADMET models, which can reduce late-stage failures.
Multiple empirical studies and industry case reports aggregated in the narrative review demonstrating improved in silico toxicity/ADMET prediction performance in specific settings; heterogeneity across datasets and endpoints; not a formal meta-analysis.
AI can reduce time-to-market and lower some drug development costs.
Synthesis of case studies, industry reports, and empirical studies reported in the narrative review that document examples of compressed timelines and cost savings in parts of the pipeline; review notes lack of long-run, generalized ROI estimates.
AI is materially accelerating discovery and development steps in pharmaceutical R&D, improving target identification, lead optimization, safety prediction, and adaptive trial design.
Narrative review synthesizing published studies, review articles, industry and regulatory reports; evidence primarily consists of empirical studies and case studies covering preclinical and clinical-stage applications. No pooled quantitative meta-analysis; heterogeneous methods and therapeutic areas.
Firms with superior proprietary data and integration capability gain competitive advantage, increasing firm-level heterogeneity in AI returns.
Narrative analysis of market structure implications and examples; no cross-firm empirical heterogeneity study included.
Returns to complementary investments (data infrastructure, experiment automation, cross-disciplinary teams) increase as AI becomes more central to discovery workflows.
Synthesis of adoption lessons and case examples emphasizing complementary capital; no quantitative ROI estimates provided.
Embedding AI into organizational processes, decision-making, and wet-lab validation is crucial to capturing its value.
Narrative review of adoption and integration lessons from large biopharma experience and illustrative case studies.
Successful AI adoption requires investment in data, talent, and workflows rather than reliance on bolt-on point solutions.
Thematic analysis of adoption-level lessons and industry case examples indicating organizational and infrastructural requirements for realized value.
AI has produced genuine early-stage breakthroughs in drug discovery, accelerating hit identification and early design cycles.
Narrative expert synthesis and thematic analysis of industry experience over the first decade of AI adoption, illustrated by early-case successes and firm-reported accelerations; no new primary experimental data or causal econometric estimates provided.
Public policies that lower frictions for secure data sharing, standardize validation metrics, and support workforce retraining can accelerate beneficial diffusion of AI while managing risks.
Policy recommendation based on the paper's synthesis of enablers and constraints; not empirically tested within the paper.
AI has the potential to reduce marginal cost and time per candidate (shorter design loops, in silico screening), increasing effective productivity of R&D spend if improvements are validated.
Theoretical and conceptual argument referencing capabilities of generative models and simulation; paper states no new quantitative estimates were produced.
Workforce upskilling and new roles (e.g., ML engineers embedded in biology teams, AI product managers) are required for effective AI integration in pharma R&D.
Descriptive projection based on observed industry hiring trends and organizational needs; no workforce survey data provided.
Cloud/federated approaches reduce upfront infrastructure investments and facilitate distributed collaboration.
Conceptual argument based on cloud economics and federated architectures; no quantitative cost-savings or collaboration metrics presented.
Cloud and federated approaches enable access to powerful pre-trained or fine-tunable models while allowing proprietary data to remain controlled (privacy-preserving sharing and model-to-data patterns).
Technological synthesis and examples of federated learning and cloud-hosted ML patterns; no empirical performance or privacy-utility tradeoff measurements reported.
Startups can leverage pre-trained models, cloud compute, and hosted toolchains to compete on speed and niche innovation against larger incumbents.
Conceptual observation and illustrative examples; not supported by systematic comparison of startup vs incumbent performance metrics in the paper.
AI lowers entry costs for smaller biotech by enabling faster molecular design, simulation, and iteration, allowing earlier translation to clinical stages.
Argument grounded in current capabilities (pre-trained models, cloud compute) and illustrative startup examples; no empirical cost or time-to-clinic data provided.
Production-first democratization builds user-friendly, productionized AI tools that non-specialists can use, decentralizing model use and accelerating throughput.
Narrative examples and conceptual reasoning in the editorial; lacks systematic evaluation of throughput gains or decentralization effects.
Culture-centric transformation embeds AI into everyday scientific and operational decisions and requires organizational change, incentives, and cross-functional workflows.
Conceptual argument and organizational theory applied in the editorial; no empirical measurement of organizational change or success rates provided.
Partnership-driven acceleration lets pharma access AI capabilities rapidly via alliances with AI/tech firms while allowing pharma to preserve focus on core drug expertise and outsource model or platform development.
Qualitative description and illustrative examples in the editorial; not supported by systematic case study data or quantified outcomes.
DAOs enable distributed collaboration among scientists, patients, and funders to prioritize projects and share results.
Stakeholder mapping and qualitative case descriptions indicating multi-stakeholder participation in DAO projects; no quantitative cross-stakeholder collaboration metrics provided.
DAOs can incentivize contribution with token rewards, milestone-based disbursements, and revenue-sharing/licensing arrangements.
Review of DAO reward and tokenomic mechanisms in the literature and case examples; conceptual synthesis rather than empirical testing of incentive effectiveness.
DAOs democratize decision-making through on-chain voting and reputation systems (example: VitaDAO).
Case-study description of VitaDAO governance structure using on-chain voting and reputation mechanisms documented in public governance records and whitepapers.
DAOs can pool capital via tokenized funding and fractionalized IP ownership (example: Molecule).
Case-study description and documentation of Molecule's marketplace and tokenization mechanisms from public sources; demonstration of mechanisms rather than measured financing outcomes at scale.
Early case studies (VitaDAO, Molecule) demonstrate proof-of-concept for tokenized fundraising, collaborative decision-making, and open-science IP models.
Comparative qualitative case-study descriptions based on public documentation, whitepapers, and governance records for two projects (VitaDAO and Molecule); no controlled or longitudinal outcome metrics reported.
Decentralized Autonomous Organizations (DAOs) present a viable alternative governance and financing model for the pharmaceutical industry that can reduce frictions in drug discovery and development, increase stakeholder participation (scientists, patients, funders, regulators), and accelerate innovation.
Conceptual/review analysis synthesizing literature on DAOs and decentralized science plus comparative case-study analysis of two early projects (VitaDAO and Molecule); no original empirical trials or large-N quantitative evaluation.
Regulators should anticipate new forms of intangible capital and data monopolies arising from sensory models and consider standards for data interoperability, public datasets/models, and workforce retraining.
Policy recommendation based on foresight and literature on data governance and platform regulation; no empirical regulatory impact analysis provided.
Economics of AI in food must incorporate non-price metrics (perceptual quality, cultural fit) and design ways to monetize and protect sensory intellectual property (trade secrets, data governance).
Normative policy and methodological recommendation derived from literature synthesis and conceptual analysis; not validated with empirical economic valuation studies.